Introduction
In recent years, ambitious global commitments have been made to improve programmes for the prevention of motherto-child transmission (PMTCT) of human immunodeficiency virus (HIV). In 2011, the Global Plan was launched to "eliminate infant HIV infections by 2015 and keep their mothers alive". 1 While the target was not reached, the initiative contributed to a 60% decline in infant infections from 270 000 to 110 000 between 2009 and 2015 across 21 priority countries in sub-Saharan Africa. 2 More recently, the Joint United Nations Programme on HIV/AIDS (acquired immune deficiency syndrome) set targets to reach 95% of pregnant women living with HIV with sustained, lifelong HIV treatment, and to reduce the annual number of newly infected children to less than 40 000 by the end of 2018 globally. 3 Option B+ is the lifelong provision of antiretroviral therapy (ART) for all HIV-positive pregnant and breastfeeding women regardless of immune status. The Global Plan has been credited with accelerating implementation of Option B+ 2, 4 and improving coverage of PMTCT services for mothers and infants. By 2014, antenatal HIV testing exceeded 90% in many eastern and southern African countries. 5 By the end of 2015, more than 80% of pregnant women living with HIV in the 21 Global Plan countries were receiving ART for PMTCT, and of an estimated 1.2 million HIV-exposed infants, 51% (612 000) were receiving an HIV test within two months of birth. 6 However, despite this progress, retention of women in HIV care during the pregnancy and postpartum period continues to be challenging. 7 Higher dropout rates have been documented after delivery and at two years of follow-up, suggesting that service integration and linking mothers to routine ART services are important determinants of retention in care. [8] [9] [10] As well as being detrimental to their own health, losing mothers from care contributes to higher HIV transmission risks to their infants, and poorer uptake of services across the cascade of infant care.
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The timing of adoption and roll-out of PMTCT policies, and the extent to which policies are implemented within health facilities, will be important in determining whether countries meet global targets for mothers living with HIV and their infants. Furthermore, how well-prepared health systems are to cope with the changes is crucial to the success of these evolving programmes. This is particularly so in rural areas where most pregnant women in sub-Saharan Africa reside, and where policy implementation may be delayed or patchy. 12 As policy changes lead to increasing client numbers, PMTCT programmes have faced challenges in ensuring sufficient supplies of HIV test kits and antiretroviral (ARV) drugs, particularly in rural areas. 13 Stock-outs of supplies may undermine client Objective To assess adoption of World Health Organization (WHO) guidance into national policies for prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) and to monitor implementation of guidelines at facility level in rural Malawi, South Africa and the United Republic of Tanzania. Methods We summarized national PMTCT policies and WHO guidance for 15 indicators across the cascades of maternal and infant care over 2013-2016. Two survey rounds were conducted (2013-2015 and 2015-2016) in 46 health facilities serving five health and demographic surveillance system populations. We administered structured questionnaires to facility managers to describe service delivery. We report the proportions of facilities implementing each indicator and the frequency and durations of stock-outs of supplies, by site and survey round. Findings In all countries, national policies influencing the maternal and infant PMTCT cascade of care aligned with WHO guidelines by 2016; most inter-country policy variations concerned linkage to routine HIV care. The proportion of facilities delivering post-test counselling, same-day antiretroviral therapy (ART) initiation, antenatal care and ART provision in the same building, and Option B+ increased or remained at 100% in all sites. Progress in implementing policies on infant diagnosis and treatment varied across sites. Stock-outs of HIV test kits or antiretroviral drugs in the past year declined overall, but were reported by at least one facility per site in both rounds. Conclusion Progress has been made in implementing PMTCT policy in these settings. However, persistent gaps across the infant cascade of care and supply-chain challenges, risk undermining infant HIV elimination goals.
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confidence and affect programme coverage. Increased patient numbers are not always offset by the recruitment of additional trained personnel, contributing to concerns around the quality of care. 13, 14 To address the programmatic challenges which are preventing countries from reaching global PMTCT targets, a better understanding is needed of the extent to which national policies align with World Health Organization (WHO) guidance. We also need data about implementation gaps at the facility level and the consequences for managing supplies of drugs and diagnostic tests. Although previous research has investigated HIV policy adoption and implementation in sub-Saharan Africa, 12, [15] [16] [17] [18] [19] few studies have documented implementation of PMTCT policies, especially after implementation of Option B+, and in rural settings. This paper used data from policy reviews and health-facility surveys conducted with health workers between 2013 and 2016 in five health and demographic surveillance system sites in rural Malawi, South Africa and the United Republic of Tanzania. The aim was to assess whether the WHO guidance on PMTCT has been adopted in national policies and implemented by rural health facilities. As a secondary objective, we assessed the frequency and duration of stockouts of HIV test kits and drug supplies over the same period.
Methods

Study settings
We purposively selected three out of six countries participating in a wider mortality study being conducted in health and demographic surveillance system sites by the network for Analysing Longitudinal Population HIV/AIDS data in Africa. 20, 21 These countries were chosen to represent a range of adoption dates of Option B+ (Malawi: 2011; South Africa: 2015; United Republic of Tanzania: 2013) and mother-to-child transmission rates (8.9% in Malawi; 5.3% in South Africa; 12.2% in the United Republic of Tanzania). [22] [23] [24] The five sites are served by 46 health facilities providing HIV services to approximately 400 000 residents 21 ( Table 1) .
HIV policy review
In 2013, we conducted a review of WHO guidance and national HIV policies from 2003 to 2013, covering HIV testing, PMTCT and ART provision. 25 In 2016, we updated the review for the period 2013 to 2015. The first phase involved a review of the literature and consultation with 28 HIV researchers and practitioners to define a conceptual framework with five main areas of health-service factors relating to delivery of HIV testing, PMTCT and ART services (service access and coverage; quality of care; coordination of care and patient tracking; support to people living with HIV; and medical management). 25 We devised 54 associated policy indicators and included all 15 that pertained to PMTCT in this study. The second phase involved reviewing WHO guidelines and national policy documents. We retrieved these through online searches of websites of health ministries and national HIV organization or through email communications or in-person visits with representatives of organizations. Documents were in- 
Health-facility surveys
We conducted surveys of health facilities between August 2013 and January 2015 (round 1), and between May 2015 and June 2016 (round 2; Table 1 ). The questionnaire was informed by the WHO service availability and readiness assessment tool, 26 and covered the delivery of HIV testing, PMTCT and ART services, as described previously. 17 We conducted survey questionnaires face-to-face, in English, with the staff in charge at each facility. Interviewers observed the availability of treatment guidelines and consulted pharmacy records for drug stocks and availability of test kits.
All health facilities providing HIV services to the health and demographic surveillance system populations were surveyed, except one small private clinic in Karonga, one public facility in Agincourt and facilities serving fewer than 100 patients per month in Ifakara. In uMkhanyakude and Kisesa, we also included facilities outside the site area, but used by health and demographic surveillance system residents. 17 For this analysis, we only included facilities that participated in both survey rounds and offered PMTCT services.
We conducted all analysis in Stata, version 15 (Stata Corp., College Station, USA). We recoded categorical variables as binary variables to demonstrate the proportion of facilities that were fully compliant with each policy (versus partial or non-compliance). We then used descriptive statistics to show the proportion of facilities implementing each policy, by survey round and site. HIV test kit and drug stock-outs were recorded for the previous year with median durations for the longest stockout during this period recorded in days.
Ethical approval was obtained locally for each site and from the London School of Hygiene and Tropical Medicine (no. 8891-1). Survey participants provided written informed consent.
Results
Policy review
We reviewed 10 WHO guidelines and 47 national policy documents (Box 1). By 2016, national policies influencing the maternal and infant cascades of care were in line with WHO guidelines in all three countries, despite substantial variation in the years of adoption (Tables 2 and Table 3 ).
Guidance stipulating that pre-and post-test counselling should be Malawi also adopted same-day ART initiation and Option B+ policies before WHO first issued its guidance. WHO recommendations from 2006 relating to linkage of mothers to routine ART care specify the need for clear guidance on when HIV-positive pregnant women should be referred from antenatal care to ART clinics, without indicating when it should occur. We noted variation in the timing of referral of pregnant or postpartum women to ART clinics in the study countries, with Malawi and South African policies stipulating that this should occur within 42 days after delivery. In the United Republic of Tanzania, the policy stipulating referral within 42 days was replaced in 2013 to allow ART provision for mothers in reproductive health clinics until their child reaches 2 years old. WHO guidance on infant diagnosis, prophylaxis and treatment were released in 2010. All countries aligned themselves with the WHO recommendations, with variations in the year of adoption.
Health facility survey
We included survey data from 46 health facilities serving the populations of the five health and demographic surveillance system sites (Table 4) .
Maternal care cascade
Provider-initiated testing and counselling was offered by all facilities in all sites for both rounds ( Table 5 ). The greatest increases in the proportion of facilities always offering both pre-and post-test counselling were seen in Kisesa: from 29% (2/7) to 86% (6/7) for pre-test counselling and from 57% (4/7) to 100% (7/7) for post-test counselling. In the Malawian and South African sites, all facilities implemented Option B+ during round 1. Implementation of Option B+ was later in the United Republic of Tanzania, with 55% (6/11) of facilities in Ifakara and 71% (5/7) of facilities in Kisesa delivering Option B+ by round 1, increasing to 100% in both sites by round 2. The proportion of facilities offering women ART services on the same day as receiving an HIV diagnosis at antenatal care increased or remained stable over the two rounds, reaching at least 91% by round 2 in all sites.
All five facilities in Karonga and 87% (20/23) in the South African sites reported making referrals by 6 weeks postpartum in round 1 with little change in round 2. In the Tanzanian sites, 72% (13/18) of health facilities reported making maternal referrals within this timeframe in round 1, dropping to 6% (1/18) by round 2. The proportion of facilities reporting that health workers accompanied women to routine ART services declined by round 2 in all sites except Karonga. The location of ART provision for PMTCT also changed over the two rounds (Fig. 1 ).
Infant care cascade
Facility-level implementation of early infant diagnosis between 4-6 weeks by round 2 was high with little variation between sites and countries (Table 6) . However, the provision of infant prophylaxis was different between sites. In the South African sites, the proportion of facilities providing prophylaxis at 4-6 weeks decreased from 87% (20/23) to 61% (14/23), with a similar decrease in the proportion of facilities providing prophylaxis until the cessation of breastfeeding, from 70% (16/23) to 61% (14/23). In the Malawian and Tanzanian sites, all facilities provided prophylaxis at 4-6 weeks by round 2.
The provision of infant feeding counselling was consistently high in all sites over both rounds. Infant care was offered in all facilities across both rounds in the two South African sites, increasing in Ifakara from 82% (9/11) to 90% (10/11), but decreasing in Karonga (100%; 5/5 to 80%; 4/5) and Kisesa (57%; 4/7 to 43%; 3/7).
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Supply stock-outs
The proportion of facilities reporting no stock-outs of HIV test kits in the year before the survey varied by round and site (Fig. 2) . The Malawian and South African sites had the highest proportion of facilities reporting no stock-outs across both rounds. In both Tanzanian sites, the proportion of facilities experiencing no stock-outs of HIV test kits in the past year was low, ranging from 0% to 30% in the two rounds. The median duration of the longest HIV test kit stock-outs in both South African sites was less than 2 weeks in both rounds (Fig. 3) . In Karonga, the median duration of the longest stock-outs decreased from 105 days to 28 days between round 1 and 2.
In the United Republic of Tanzania, the median duration of the longest stockouts was 90 days and 75 days in Ifakara and Kisesa, respectively, in round 1, decreasing to between 30 days and 60 days, respectively, by round 2. A similar pattern was reported for maternal ARV drugs, with all sites having a higher proportion of facilities reporting no stock-outs by round 2 (or maintaining 100% of facilities reporting no stock-outs) except Ifakara. In Ifakara fewer facilities reported no maternal drug stock-outs by round 2; however, the median duration of the longest stock-out declined from 45 to 21 days over the two rounds.
In all sites, the proportion of facilities reporting no stock-outs of infant ARV drugs increased or remained at 100% in all sites over the two rounds. The median duration of the longest stock-outs declined over the two rounds from 60 to 5 days in Ifakara and from 37 to 7 days in Kisesa.
Discussion
Our study shows overall progress in delivering PMTCT services in five rural settings in Africa in line with WHO guidance, despite some implementation gaps and persistent supply-chain challenges. We found that in all study countries, national policies influencing the maternal and infant PMTCT cascade aligned with WHO guidelines by 2016, despite considerable variation in the year of adoption. Malawi was notable in having adopted several policies before their recommendation by WHO, including same-day ART initiation and Option B+, and other countries have drawn lessons from Malawi's experience. 27 Over the study period, all sites improved the proportion of facilities that were implementing policies designed to improve ART coverage among pregnant women. These policies include integration of ART services into antenatal care, sameday initiation of ART and documentation of transfers from PMTCT into routine HIV care. These findings provide further evidence of progress achieved in these countries during the Global Plan years, contributing to ART coverage among pregnant women of 65%, 90% and > 95% in Malawi, the United Republic of Tanzania and South Africa respectively.
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Our findings suggest that most of the variation across countries in the adoption and implementation of PMTCT policy concerned the delivery of HIV care within antenatal care services, including the timing of the mothers' transfer to routine HIV care from antenatal clinics. Timings varied from 42 days following delivery in Malawi and South Africa, to 2 years after delivery in the United Republic of Tanzania. This variation is likely explained by the broad guidance provided by WHO, and perhaps illustrates the lack of evidence on the relative merits of each strategy. 28 In particular, the extent to which these policy differences influence mothers' retention in care is unclear, with high drop-out rates after transfer to routine care reported in some settings, regardless of the timing of the referral. 8, 29 Further research should investigate the impact of service integration on PMTCT outcomes, and explore the perspectives of service providers and users on different models to inform future policy refinements.
Although infant testing, prophylaxis and treatment policies were well- ... continued established in all three countries, implementation was not universal across the surveyed facilities, with variation within and between countries, and over survey rounds. Patchy implementation of these policies may be explained by insufficient capacity or resources, particularly in rural areas, and may help to explain why improvements in infant outcomes have lagged behind those in maternal outcomes in these countries. 2 Our findings align with other studies that suggest that greater focus is needed on service implementation across the infant cascade of care if progress towards global targets for infants is to be accelerated. 30 The introduction of Option B+ led to concerns that health systems may be insufficiently prepared for the resulting increase in client numbers. Our findings suggest that supplying sufficient HIV test kits to meet demand in these rural areas was a persistent challenge, with all sites still reporting stock-outs by round 2. Stock-outs of HIV test kits may undermine women's confidence in the HIV services being offered, 31 and may help to explain the persistently low uptake of HIV testing in some settings, including the United Republic of Tanzania. 32 The overall reduction in maternal and infant ARV drug stock-outs between survey rounds, as well as in the median duration of the longest stock-out in the past 12 months, may indicate the success of Option B+ in simplifying drug forecasting, procurement and stock monitoring. 33 These findings also suggest that concerns that Option B+ may over-burden health systems through increased client numbers have not been realized with regards to drug supply chains. 34 Nevertheless, further evidence is needed to understand the impacts of Option B+ on other aspects of health systems including on the workforce and service delivery mechanisms such as integration. 35 Our study has various limitations, including potential reporting bias given that survey responses were obtained from facility staff who may be inclined to overestimate some measures of service delivery. Reporting bias was minimized District hospital or large hospital
Referral hospital
HIV: human immunodeficiency virus. a In uMkhanyakude 10 facilities were outside that system and in Kisesa 3 facilities were outside the health and demographic surveillance system. b In Kisesa 1 of the 7 facilities were government-run, but managed by a faith-based organization. Note: n is the total number of facilities offering antenatal care and prevention of mother-to-child transmission services participating in health and demographic surveillance system surveys at that site. National authorities should decide whether health services will principally counsel mothers to either exclusively breastfeed and receive ART interventions or avoid all breastfeeding, as the strategy that will most likely give infants the greatest chance of HIVfree survival. Where breastfeeding is judged to be the best option: exclusively breastfeed for the first 6 months, introduce appropriate complementary food thereafter, and continue breastfeeding for 12 months; wean gradually within 1 month HIV care in Africa Harriet Jones et al. Table 5 . 
HIV testing
Provider-initiated testing and counselling provided in antenatal care
5 (100) 5 (100) 6 (100) 6 (100) 17 (100) 17 (100) 11 (100) 11 (100) 7 (100) 7 (100) Pre-test counselling always given 4 (80)
5 (100) 6 (100) 6 (100) 17 (100) 17 (100) 10 (91) 9 (82) 2 (29) 5 (100) 6 (100) 6 (100) 17 (100) 16 (94) 8 (73) a 10 (91) 4 (57) 7 (100)
Treatment initiation
Option B+ implemented 5 (100)
5 (100) 6 (100) 6 (100) 17 (100) 17 (100) 6 (55) 11 (100) 5 (71) 7 (100) HIV treatment services given on same day as antenatal care services 5 (100)
5 (100) 6 (100) 6 (100) 16 (94) 17 (100) 6 (56) 10 (91) 6 (86) 7 (100) ART for pregnant women testing HIV-positive provided in the same building as antenatal care
3 (60) 4 (80) 6 (100) 6 (100) 11 (65) 15 (88) 5 (46) 11 (100) 6 (86) 6 (86) a
Linkage to care
Women are referred to ART clinics from PMTCT during antenatal care or by 6 weeks post-delivery 5 (100)
5 (100) 5 (83) 5 (83) 15 (88) 14 (82) 6 (56) 0 (0) 7 (100) 1 (14) Maternal referrals to HIV care and treatment services from PMTCT are documented 5 (100)
5 (100) 6 (100) 4 (67) 17 (100) 16 (94) 10 (91) 11 (100) 6 (86) 7 (100) Health worker accompanies woman during initial referral to routine ART services 4 (80)
4 (80) 5 (83) 4 (67) 5 (29) 4 (24) 9 (82) 3 (27) 3 (43) 1 (14) Check if woman arrives in routine ART services 5 (100)
5 (100) 6 (100) 5 (83) a 17 (100) 13 (77) 10 (91) 1 (9) a 5 (71) 7 (100) ART: antiretroviral therapy; HIV: human immunodeficiency virus; PMTCT: prevention of mother-to-child transmission.
a Missing data from 1 facility in survey round.
Note: n is the total number of facilities offering antenatal care and prevention of mother-to-child transmission services participating in health and demographic surveillance system surveys at that site.
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for some indicators by triangulating responses with observations in the facilities, including for availability of treatment guidelines. We also consulted pharmacy records to validate reports of drug stocks and test availability. Our data cover the period from 2013 to 2016, and the accelerated roll-out of universal Test and Treat 28 since 2016 may have led to changes in implementation of Option B+ policies. Furthermore, the timing of survey rounds differed between countries, making it difficult to compare the findings across settings. We selected facilities because they served the health and demographic surveillance system site populations; therefore, facilities were not nationally representative and this limits the generalizability of our findings. However, the facilities can be considered typical of those found in rural areas in each country. Using a similar analytical approach, data from national- Table 6 . Same building as antenatal care
Same facility but different building to antenatal care
In another facility
Location of ART Provision
Round 1 Round 2
ART: antiretroviral therapy; HIV: human immunodeficiency virus. Note: Total number of facilities: Karonga (n = 5); Agincourt (n = 6); uMkhanyakude (n = 17); Ifakara, (n = 11); Kisesa (n = 7).
ly representative health-facility surveys (e.g. those using service availability and readiness assessment methods) could be used for future assessments of HIV policy implementation. Finally, further investigations are needed to understand why gaps occur and how these may be addressed, as well as to assess the proportion of clients that receive care in line with national guidelines and the impact of policy implementation on patient outcomes, including retention in care, mortality or ART coverage.
In conclusion, we found general alignment of national PMTCT policies with WHO guidance, and substantial progress in their facility-level implementation in five rural African settings between 2013 and 2016. However, gaps in implementation of infant care policies persisted in all sites, threatening to undermine efforts to eliminate new infant HIV infections by 2020. Concerns that supply chains could not cope with additional client numbers from PMTCT policy changes have not been met, although occurrences of stock-outs may undermine progress if the causes are not addressed. ■ Результаты Во всех странах национальные стратегии, влияющие на цепочку предоставления услуг в отношении материнского и детского РМТСТ, были приведены в соответствие с рекомендациями ВОЗ к 2016 г. Большинство вариантов стратегий в разных странах касались привязки к плановому лечению ВИЧ-инфицированных. Доля медицинских учреждений, предоставляющих возможность консультации после тестирования, начала антиретровирусной терапии (АРТ) в тот же день, дородового лечения и АРТ в том же здании, а также предоставляющих вариант В+, выросла или осталась на уровне 100% во всех обследованных зонах. Прогресс во внедрении стратегий диагностики и лечения младенцев различался в зависимости от зоны исследования. Дефицит тест-систем для выявления антител к ВИЧ или антиретровирусных препаратов за последний год в целом уменьшился, но сообщения о нехватке поступали по меньшей мере из одного учреждения в каждой зоне в течение обоих опросов. Вывод Наблюдается прогресс во внедрении стратегий PMTCT в указанных условиях. Однако постоянные недочеты в цепочке предоставления услуг младенцам и проблемы с поставками могут поставить под угрозу цели по устранению ВИЧ у младенцев.
Resumen
Aplicación de políticas de prevención de la transmisión del VIH de madre a hijo en las zonas rurales de Malawi, la República Unida de Tanzanía y Sudáfrica, 2013-2016
Objetivo Evaluar la adopción de las directrices de la Organización Mundial de la Salud (OMS) en las políticas nacionales de prevención de la transmisión del virus de la inmunodeficiencia humana (VIH) de madre a hijo y supervisar la aplicación de las directrices a nivel de las instalaciones sanitarias en las zonas rurales de Malawi, la República Unida de Tanzanía y Sudáfrica. Métodos Resumimos las políticas nacionales de PTMI y las directrices de la OMS para 15 indicadores en toda la serie de servicios de atención maternoinfantil durante el período 2013-2016. Se realizaron dos rondas de encuestas (2013-2015 y 2015-2016) en 46 instalaciones sanitarias que atienden a cinco poblaciones del sistema de vigilancia sanitaria y demográfica. Se administraron cuestionarios estructurados a los gestores de las instalaciones para describir la prestación de servicios. Informamos las proporciones de las instalaciones que aplican cada indicador y la frecuencia y duración de la falta de existencias de suministros, por emplazamiento y ronda de encuestas. Resultados En todos los países, las políticas nacionales que influyen en la serie de servicios de atención maternoinfantil de la PTMI se ajustaron a las directrices de la OMS para 2016; la mayoría de las variaciones de las políticas entre países se referían a la vinculación con la atención habitual de la infección por el VIH. La proporción de instalaciones que ofrecen asesoramiento posterior a la prueba, iniciación de la terapia antirretrovírica en el mismo día, atención prenatal y suministro de terapia antirretrovírica en el mismo edificio, y la Opción B+ aumentaron o se mantuvieron en el 100 % en todos los emplazamientos. El progreso en la aplicación de las políticas de diagnóstico y tratamiento del lactante varió de un emplazamiento a otro. Las existencias de kits de pruebas del VIH o de medicamentos antirretrovirales se redujeron en general en el último año, pero en ambas rondas se informó de la existencia de al menos una instalación por emplazamiento. Conclusión Se ha progresado en la aplicación de la política de PTMI en estos ámbitos. Sin embargo, las persistentes brechas en la serie de servicios de atención infantil y los desafíos de la cadena de suministro pueden socavar los objetivos de eliminación del VIH infantil.
